Literature DB >> 29773063

Conversion of Protein Active Regions into Peptidomimetic Therapeutic Leads Using Backbone Cyclization and Cycloscan - How to Do it Yourself!

Samuel J S Rubin1, Yftah Tal-Gan2, Chaim Gilon3, Nir Qvit4.   

Abstract

Protein-protein Interactions (PPIs) are particularly important for controlling both physiologic and pathologic biological processes but are difficult to target due to their large and/or shallow interaction surfaces unsuitable for small molecules. Linear peptides found in nature interact with some PPIs, and protein active regions can be used to design synthetic peptide compounds for inhibition of PPIs. However, linear peptides are limited therapeutically by poor metabolic and conformational stability, which can compromise their bioactivity and half-life. Cyclic peptidomimetics (modified peptides) can be used to overcome these challenges because they are more resistant to metabolic degradation and can be engineered to adopt desired conformations. Backbone cyclization is a strategy that we developed to improve drug-like properties of linear peptide leads without jeopardizing the integrity of functionally relevant side-chains. Here, we provide the first description of an entire approach for developing backbone cyclized peptide compounds, based upon two straightforward 'ABC' and 'DEF' processes. We present practical examples throughout our discussion of revealing active regions important for PPIs and identifying critical pharmacophores, as well as developing backbone cyclized peptide libraries and screening them using cycloscan. Finally, we review the impact of these advances and provide a summary of current ongoing work in the field. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Backbone cyclization; cyclization; peptides; peptidomimetics; protein-protein interactions; therapeutic.

Mesh:

Substances:

Year:  2018        PMID: 29773063      PMCID: PMC6050105          DOI: 10.2174/1568026618666180518094322

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  57 in total

1.  Proteinminus signProtein Interactions: Interface Structure, Binding Thermodynamics, and Mutational Analysis.

Authors:  Wesley E. Stites
Journal:  Chem Rev       Date:  1997-08-05       Impact factor: 60.622

Review 2.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

3.  Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: the HIV-1 CD4:gp120 paradigm.

Authors:  Mattan Hurevich; Avi Swed; Salim Joubran; Shira Cohen; Noam S Freeman; Elena Britan-Rosich; Laurence Briant-Longuet; Martine Bardy; Christian Devaux; Moshe Kotler; Amnon Hoffman; Chaim Gilon
Journal:  Bioorg Med Chem       Date:  2010-04-21       Impact factor: 3.641

Review 4.  Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding.

Authors:  Domingo González-Ruiz; Holger Gohlke
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 5.  Peptidomimetics, a synthetic tool of drug discovery.

Authors:  Josef Vagner; Hongchang Qu; Victor J Hruby
Journal:  Curr Opin Chem Biol       Date:  2008-05-14       Impact factor: 8.822

Review 6.  Peptides and peptidomimetics as regulators of protein-protein interactions.

Authors:  Anna D Cunningham; Nir Qvit; Daria Mochly-Rosen
Journal:  Curr Opin Struct Biol       Date:  2017-01-04       Impact factor: 6.809

7.  Developing potent backbone cyclic peptides bearing the shared epitope sequence as rheumatoid arthritis drug-leads.

Authors:  Shirly Naveh; Yftah Tal-Gan; Song Ling; Amnon Hoffman; Joseph Holoshitz; Chaim Gilon
Journal:  Bioorg Med Chem Lett       Date:  2011-11-04       Impact factor: 2.823

8.  A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway.

Authors:  Pninit Litman; Osnat Ohne; Shirly Ben-Yaakov; Liron Shemesh-Darvish; Tamar Yechezkel; Yosef Salitra; Shai Rubnov; Ilana Cohen; Hanoch Senderowitz; Dvora Kidron; Oded Livnah; Alexander Levitzki; Nurit Livnah
Journal:  Biochemistry       Date:  2007-03-31       Impact factor: 3.162

9.  Dissecting the energetics of an antibody-antigen interface by alanine shaving and molecular grafting.

Authors:  L Jin; J A Wells
Journal:  Protein Sci       Date:  1994-12       Impact factor: 6.725

10.  Design and synthesis of backbone cyclic phosphorylated peptides: The IkappaB model.

Authors:  Nir Qvit; Ada Hatzubai; Deborah E Shalev; Assaf Friedler; Yinon Ben-Neriah; Chaim Gilon
Journal:  Biopolymers       Date:  2009-02       Impact factor: 2.505

View more
  4 in total

1.  De Novo Development of Mitochondria-Targeted Molecular Probes Targeting Pink1.

Authors:  Shulamit Fluss Ben-Uliel; Faten Habrat Zoabi; Moriya Slavin; Hadas Sibony-Benyamini; Nir Kalisman; Nir Qvit
Journal:  Int J Mol Sci       Date:  2022-05-28       Impact factor: 6.208

2.  Cyclizing Painkillers: Development of Backbone-Cyclic TAPS Analogs.

Authors:  Alaa Talhami; Avi Swed; Shmuel Hess; Oded Ovadia; Sarit Greenberg; Adi Schumacher-Klinger; David Rosenthal; Deborah E Shalev; Mattan Hurevich; Philip Lazarovici; Amnon Hoffman; Chaim Gilon
Journal:  Front Chem       Date:  2020-11-12       Impact factor: 5.221

3.  Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2.

Authors:  Masoumeh Sadat Mousavi Maleki; Mosayeb Restamian; Hamid Madanchi
Journal:  Expert Rev Anti Infect Ther       Date:  2021-04-12       Impact factor: 5.091

4.  Targeting protein-protein interaction for immunomodulation: A sunflower trypsin inhibitor analog peptidomimetic suppresses RA progression in CIA model.

Authors:  Achyut Dahal; Pravin Parajuli; Sitanshu S Singh; Leeza Shrestha; Jafrin Jobayer Sonju; Prajesh Shrestha; Ioulia Chatzistamou; Seetharama Jois
Journal:  J Pharmacol Sci       Date:  2022-04-25       Impact factor: 3.578

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.